Multiple Myeloma in Patients over 80: A Real World Retrospective Study of First Line Conservative Approach with Bortezomib Dexamethasone Doublet Therapy and Mini-Review of Literature

SIMPLE SUMMARY: Multiple Myeloma (MM) is frequent and represents 2% of all cancers. Daratumumab bortezomib-melphalan-prednisone (D-VMP) and daratumumab lenalidomide dexamethasone (D-Rd) are considered the standard of care for elderly patients with newly diagnosed MM (NDMM), defined as transplant-ine...

Descripción completa

Detalles Bibliográficos
Autores principales: Huynh, Laurence, Birsen, Rudy, Mora, Lucie, Couderc, Anne-Laure, Mitha, Nathalie, Farcet, Anaïs, Chebib, Amale, Chaibi, Pascal
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9564122/
https://www.ncbi.nlm.nih.gov/pubmed/36230662
http://dx.doi.org/10.3390/cancers14194741

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9564122/
https://www.ncbi.nlm.nih.gov/pubmed/36230662
http://dx.doi.org/10.3390/cancers14194741

Ejemplares similares